KLRK1 and neoplasm: This integrative approach, from receptor‐ligand biology to tumour immunometabolism, clarifies how NK activation thresholds are shaped within the tumour microenvironment and guides rational design of interventions to restore NKG2D‐dependent antitumor responses.